Gadolinium Side Effects Lawsuit
The FDA has released a public health advisory concerning Gadolinium based MRI contrasting agents warning about an increased risk of nephrogenic systemic fibrosis (NSF). If you or a loved one have experienced Gadolinium side effects you may be entitled to compensation. Contact the Gadolinium Lawyers of Ennis & Ennis, P.A. today for a free, confidential case evaluation.
 
Gadolinium Lawsuit
Gadolinium Side Effects Lawsuit
Gadolinium News

Ennis & Ennis, P.A. is representing individuals that have been harmed as a result of Gadolinium side effects. If you or a loved one have been harmed as a result of Gadolinium use you may be entitled to compensation. Click here to contact one of our Gadolinium Attorneys about a Gadolinium lawsuit today.

 

 

FDA Medication Guide

Gadolinium Imaging Contrast Agents
May 23, 2007 – the Food and Drug Administration (FDA) issued a public health advisory warning the public regarding recent findings that Gadolinium based MRI contrasting agents significantly increases the risk of Nephorgenic Systemic Fibrosis (NSF). Currently there are 5 MRI contrasting agents that use Gadolinium:

  • OmniScan - Gadadiamide
  • OptiMARK - Gadoversetamide
  • Prohance -  Gadoteridol
  • Magnavist - Gadopentetate Dimeglumine
  • Multihance -Gadobenate Dimeglumine

Gadolinium based injections are used as an MRI contrast agent so doctors can better distinguish blood vessels from nearby tissue. For those with impaired kidney function, gadolinium based MRI contrast agents could lead to a serious and potentially fatal disorder called Nephorgenic Systemic Fibrosis.

What is Nephorgenic Systemic Fibrosis?
Nephorgenic Systemic Fibrosis is a progressive disorder which is associated with the development of excessive scar tissue and thick, hardened and tight areas of skin which often cover the joints, resulting in severe limitations on movement.  In many cases it renders the victim unable to walk or fully move the joints of their arms, hands, legs and/or feet, and they become dependent on a wheelchair within weeks of the onset.  There is no known cure or effective treatment for Nephrogenic Systemic Fibrosis, and in some cases it can lead to death.

Gadolinium Side Effects
Less severe gadolinium side effects after receiving the contrast injection could include allergic reactions which can lead to skin conditions, such as rashes, sweating, itching, hives and swelling of the face.  It can also cause irritation to the veins where it is injected, causing skin problems and possible formation of blood clots. Signs of more severe side effects may include:

  • Burning, itching, swelling, hardening and tightening of the skin
  • Red or dark patches on the skin
  • Yellow spots on the whites of the eyes
  • Stiff joints with trouble straightening or moving the limbs
  • Pain in the hip bones or ribs
  • Generalized muscle weakness

If you or a loved one have experienced Gadolinium side effects you may be entitled to compensation. Contact the Gadolinium attorneys of Ennis & Ennis today for a free confidential case evaluation. Our on staff nurse and lawyers are standing by to answer any questions you may have regarding Gadolinium side effects, a possible Gadolinium class action lawsuit, or any other type of Gadolinium litigation.


04/17/2009 - Bayer AG, Germany’s largest drugmaker, has started settling lawsuits over its Magnevist contrast agent used in diagnostic imaging tests. The company began negotiations in about 40 cases linking the product to a disease that hardens organs, Peter Burg, an attorney with Burg Simpson Eldredge Hersh Jardine PC in Englewood, Colorado, said today. More ::

04/02/2009 - Meta-analysis reveals a strong association between contrast agents and nephrogenic systemic fibrosis. Evidence suggests a potentially causal link between gadolinium-based contrast agents (GBCAs) and nephrogenic systemic fibrosis (NSF) in patients with advanced kidney disease, according to researchers. More ::

03/16/2009 - According to U.S. District Judge Dan Polster, Bayer Healthcare has initiated settlement negotiations with a number of plaintiffs who have filed Nephrogenic Systemic Fibrosis lawsuits after receiving the gadolinium-based Magnevist MRI contrast agent. More ::

03/08/2009 - The American Society of Anesthesiologists (ASA) Task Force on Anesthetic Care for Magnetic Resonance Imaging (MRI) has issued a practice advisory in this area and published it in the March issue of Anesthesiology. Anesthetic care for MRI encompasses provision of moderate and deep sedation, monitored anesthesia care, general anesthesia, and ventilatory and critical care support. More ::

01/14/2009- Cleveland, OH: Magnetic resonance imaging, known more commonly as an MRI, is one of the super tools of modern medicine. It provides doctors with a detailed picture of what’s going on deep inside a patient’s body. However, there is evidence to show that one of the chemical agents used to produce MRI can be extremely toxic to people with kidney disease. More ::

12/22/2008- Lawyers for the plaintiffs and lawyers for the manufacturers of gadolinium based MRI contract agents, have filed a joint list of 193 NSF lawsuits which are eligible to be among the first cases prepared for trial in the consolidated federal litigation. More ::

12/14/2008- A new study of people with Nephrogenic Systemic Fibrosis (NSF) has again found a strong link between the condition and the use of gadolinium contrast dyes. The study, conducted by researchers at Vanderbilt University, concludes that gadolinium contrast dyes should be used "judiciously" in patients with pre-existing kidney disease, and their benefits should be carefully weighed against their risks. More ::

 

More Gadolinium News ::
Multihance Gadolinium Lawsuit

Washington DC Office
1101 Pennsylvania Ave.
Suite 600
Washington DC 20004
Telephone: 202-756-2972

Miami Office
1111 Brickell Avenue
11th Floor
Miami, FL 33131
Telephone: 305-913-7199

Fort Lauderdale Office
110 E. Broward Blvd.
Suite 1700
Fort Lauderdale, FL 33301
Telephone: 954-315-3934
Facsimile: 954-315-3914
Free Case Evaluation. Nationwide: 1-800-856-6405